The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

Gynecologic Oncology
W J HoskinsG Omura

Abstract

Gynecologic Oncology Group Protocol 52, a randomized trial of cisplatin and cyclophosphamide with or without doxorubicin in "optimal" Stage III epithelial ovarian cancer, failed to demonstrate a significant difference in the outcome in 349 evaluable patients. Additional review of the records was carried out to determine the influence of cytoreductive surgery on survival. Since eligibility for the study was the presence of residual cancer of 1 cm or less, the influence of cytoreductive surgery could be evaluated by comparing outcome in patients presenting with large-volume extrapelvic disease, but who were cytoreduced to small-volume disease. Factors evaluated were age, cell type, grade, size, and location of disease at exploration, size, and location of residual disease after cytoreduction, number of residual nodules, ascites, type of surgery, blood loss, and hospital days. Univariate analysis revealed that age, size of residual disease, mucinous or clear cell histologic type, histologic grade, and number of residual lesions were significant prognostic factors. By univariate analysis patients found to have extrapelvic disease of 1 cm or less had a better recurrence-free interval and survival than those patients with large-volum...Continue Reading

References

Jul 1, 1984·Gynecologic Oncology·G DelgadoE S Petrilli

❮ Previous
Next ❯

Citations

Oct 3, 1999·Seminars in Surgical Oncology·T C Randall, S C Rubin
Oct 3, 1999·Seminars in Surgical Oncology·V E Herrin, J T Thigpen
Jul 7, 2000·Seminars in Surgical Oncology·I VergoteP Van Dam
Jul 1, 1994·Seminars in Surgical Oncology·R Farias-EisnerJ S Berek
Feb 18, 2011·Langenbeck's Archives of Surgery·Piers A C GatenbyAndrew C Wotherspoon
Aug 24, 2012·International Journal of Clinical Oncology·Tamotsu Sudo
Mar 2, 2011·Cancer Causes & Control : CCC·Kristin L WhiteEllen L Goode
Jun 12, 2002·Current Treatment Options in Oncology·M E van der Burg
Oct 7, 2009·Current Treatment Options in Oncology·Ginger J Gardner
Oct 14, 2005·Current Oncology Reports·Teresa P Díaz-Montes, Robert E Bristow
Oct 21, 2009·Current Oncology Reports·Peter E Schwartz
May 26, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·A Poveda VelascoUNKNOWN GEICO Group
Nov 3, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·F C Muñoz-CasaresA Gómez-Portilla
Nov 18, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Lorenzo AlonsoCamelia Baha
Nov 18, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Francisco C Muñoz-CasaresJordi Muntané
Jan 1, 1995·Critical Reviews in Oncology/hematology·M A Morgan, S C Rubin
Aug 1, 1995·Critical Reviews in Oncology/hematology·P J Hoskins
Jul 9, 2002·Obstetrics and Gynecology·Brian C CooperRichard E Buller
Sep 12, 2001·The Surgical Clinics of North America·T C Randall, S C Rubin
Aug 21, 2003·Gynecologic Oncology·Michael L Berman
Mar 7, 2002·Critical Reviews in Oncology/hematology·Alberto E Selman, Larry J Copeland
Jan 5, 2002·Journal of the American College of Surgeons·N Gillette-ClovenM F Kohler
Oct 3, 2003·Journal of the American College of Surgeons·Robert E BristowFredrick J Montz
Mar 3, 1998·Journal of the American College of Surgeons·E L Yordan
Dec 14, 2011·The Pharmacogenomics Journal·E CaiolaM Marabese
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S. Pecorelli, G. Favalli
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R. F. Ozols
Jul 30, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·C T GriffithsN J Finkler
Mar 27, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S MemarzadehR Farias-Eisner
Apr 14, 2006·The New England Journal of Medicine·Carolyn N KrasnerEsther Oliva
Dec 14, 2004·The New England Journal of Medicine·Tate Thigpen
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N ColomboUNKNOWN ESMO Guidelines Working Group
Dec 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N F Hacker
Oct 16, 1999·American Journal of Clinical Oncology·M ShimadaN Terakawa
Oct 1, 1996·Obstetrical & Gynecological Survey·J Menczer
May 11, 1999·Obstetrical & Gynecological Survey·C S ChuJ E Wheeler
Dec 29, 2000·Obstetrical & Gynecological Survey·D NunnsD Ireland
Aug 12, 2005·Current Opinion in Oncology·Philipp Harter, Andreas du Bois
Jul 18, 2006·Obstetrical & Gynecological Survey·Maryam AlhaykiTien Le

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.